234 related articles for article (PubMed ID: 29067723)
1. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
Lakshman A; Singh PP; Rajkumar SV; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs M; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
Am J Hematol; 2018 Feb; 93(2):179-186. PubMed ID: 29067723
[TBL] [Abstract][Full Text] [Related]
2. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Griffin PT; Ho VQ; Fulp W; Nishihori T; Shain KH; Alsina M; Baz RC
Cancer; 2015 Oct; 121(20):3622-30. PubMed ID: 26149422
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Togano T; Andoh S; Komuro M; Mitsui Y; Itoi S; Hirai R; Nakamura M; Tanimura A; Sekine R; Takeshita M; Miwa A; Hagiwara S
Intern Med; 2022 Nov; 61(22):3329-3334. PubMed ID: 35466165
[TBL] [Abstract][Full Text] [Related]
4. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.
Gerrie AS; Mikhael JR; Cheng L; Jiang H; Kukreti V; Panzarella T; Reece D; Stewart KA; Trieu Y; Trudel S; Chen CI
Br J Haematol; 2013 Jun; 161(6):802-10. PubMed ID: 23594335
[TBL] [Abstract][Full Text] [Related]
5. Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Randall K; Kaparou M; Xenou E; Paneesha S; Kishore B; Kanellopoulos A; Lovell R; Holder K; Suhr J; Baker L; Ryan L; Nikolousis E
Eur J Haematol; 2017 Oct; 99(4):300-305. PubMed ID: 28632322
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Sigle M; Mohyuddin GR; Coggins E; Remker C; Shune L; Mahmoudjafari Z; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e220-e226. PubMed ID: 33093009
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
9. KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.
Alsouqi A; Khan M; Dhakal B; Du L; Harrell S; Hari P; Cornell RF
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):526-535. PubMed ID: 33985931
[TBL] [Abstract][Full Text] [Related]
10. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience.
Ghandili S; Alihodzic D; Wiessner C; Bokemeyer C; Weisel K; Leypoldt LB
Ann Hematol; 2023 Jan; 102(1):117-124. PubMed ID: 36383242
[TBL] [Abstract][Full Text] [Related]
11. EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
Jamshed S; Fowler DH; Neelapu SS; Dean RM; Steinberg SM; Odom J; Bryant K; Hakim F; Bishop MR
Bone Marrow Transplant; 2011 May; 46(5):676-81. PubMed ID: 20661232
[TBL] [Abstract][Full Text] [Related]
12. Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCT.
Yhim HY; Kim K; Kim JS; Kang HJ; Kim JA; Min CK; Bae SH; Park E; Yang DH; Suh C; Kim MK; Mun YC; Eom HS; Shin HJ; Yoon HJ; Kwon JH; Lee JH; Kim YS; Yoon SS; Kwak JY
Bone Marrow Transplant; 2013 Mar; 48(3):425-32. PubMed ID: 22941384
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials.
Lakshman A; Abeykoon JP; Kumar SK; Rajkumar SV; Dingli D; Buadi FK; Gonsalves WI; Leung N; Dispenzieri A; Kourelis TV; Go RS; Lacy MQ; Hobbs MA; Lin Y; Warsame R; Lust J; Fonder AL; Hwa YL; Hayman SR; Russell SJ; Kyle RA; Gertz MA; Kapoor P
Am J Hematol; 2017 Nov; 92(11):1146-1155. PubMed ID: 28799231
[TBL] [Abstract][Full Text] [Related]
14. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Srikanth M; Davies FE; Wu P; Jenner MW; Ethell ME; Potter MN; Shaw BE; Saso RM; Dines S; Morgan GJ
Eur J Haematol; 2008 Dec; 81(6):432-6. PubMed ID: 18691254
[TBL] [Abstract][Full Text] [Related]
15. DCEP as a bridge to ongoing therapies for advanced relapsed and/or refractory multiple myeloma.
Yuen HLA; Low MSY; Fedele P; Kalff A; Walker P; Bergin K; Coutsouvelis J; Grigoriadis G; Spencer A
Leuk Lymphoma; 2018 Dec; 59(12):2842-2846. PubMed ID: 29616871
[TBL] [Abstract][Full Text] [Related]
16. DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Ainley L; Chavda SJ; Counsell N; Cheesman S; Newrick F; Horder J; Kyriakou C; Papanikolaou X; Sive J; Lee L; Wechalekar A; Mehta A; Popat R; Rabin N; Yong K
Br J Haematol; 2021 Feb; 192(3):e73-e77. PubMed ID: 33236352
[No Abstract] [Full Text] [Related]
17. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
18. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
[TBL] [Abstract][Full Text] [Related]
19. Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma.
Zhou X; Ruckdeschel A; Peter J; Böckle D; Hornburger H; Danhof S; Steinhardt MJ; Heimeshoff L; Einsele H; Kortüm KM; Rasche L
Hematol Oncol; 2022 Apr; 40(2):202-211. PubMed ID: 34796520
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients.
Romano A; Chiarenza A; Conticello C; Cavalli M; Vetro C; Di Raimondo C; Cunsolo R; Palumbo GA; Di Raimondo F
Eur J Haematol; 2014 Sep; 93(3):207-13. PubMed ID: 24673398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]